# Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer

> **NCT00022516** · PHASE3 · COMPLETED · sponsor: **ETOP IBCSG Partners Foundation** · enrollment: 1086 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT00022516
- **Lead sponsor:** ETOP IBCSG Partners Foundation
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-11
- **Primary completion:** 2015-01
- **Final completion:** 2016-08
- **Target enrollment:** 1086 (ACTUAL)
- **Last updated:** 2016-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00022516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00022516, "Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00022516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*